SMTIHealthcare · Medical Instruments & SuppliesThe 3 Wall Street analysts covering Sanara MedTech, Inc. hold a median 12-month price target of $35 — +1.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 21 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Sanara MedTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (97): The business earns solid, repeatable profits on what it owns.
Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SMTI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | $36 → $35 |
| 17 June 2026 | Freedom Broker | Initiates | Buy | $35 |
| 17 June 2026 | Freedom Broker | Initiates | Buy | — |
| 15 Apr 2026 | Lake Street | Initiates | Buy | — |
| 26 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Aug 2025 | HC Wainwright& Co. | Maintains | Buy | — |
| 15 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 26 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 23 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 23 Dec 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 May 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 Mar 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 6 Feb 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Nov 2023 | Cantor Fitzgerald | Maintains | Overweight | — |
| 26 Sept 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SMTI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 13% of US stocks
Cheaper than 43% of US stocks
Cheaper than 2% of US stocks
Cheaper than 10% of US stocks
Higher than 50% of US stocks
Higher than 57% of US stocks
Higher than 98% of US stocks
Higher than 57% of US stocks
Higher than 13% of US stocks
Higher than 42% of US stocks
Higher than 87% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sanara MedTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sanara MedTech Inc. reported Q2 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.02 per share. This compares favorably to a loss of $0.23 per share in the same quarter last year.
Why it matters — The company exceeded analyst expectations and showed a significant year-over-year improvement, swinging from a loss to profitability.
Sanara MedTech Inc. reported its unaudited financial results for the second quarter ended June 30, 2026. The announcement covers the company's performance for the period in its surgical market focus.
Why it matters — SMTI watchers would care because the quarterly financial results provide a regular update on the company's operational and financial performance.
Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations involving several companies, including Sanara MedTech Inc. (Nasdaq – SMTI). The firm invites shareholders to discuss the investigation at no cost or financial obligation.
Why it matters — The notice signals that Sanara MedTech is the subject of a law-firm investigation, which could be of concern to SMTI watchers and shareholders.
Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti Jr., announced it is investigating the proposed sale of Sanara MedTech Inc. to MiMedx Group, Inc. Under the deal terms, Sanara shareholders would receive $33.00 in cash and 0.4735 MiMedx shares per Sanara share, and the firm is examining the adequacy of the price and process of the transaction.
Why it matters — An investigation into whether the proposed sale price and process adequately compensate Sanara shareholders could affect the outcome or scrutiny of the transaction for SMTI holders.
Brodsky & Smith has announced investigations involving multiple companies, including Sanara MedTech Inc. (SMTI), and is inviting shareholders to discuss the matter at no cost.
Why it matters — The investigation announcement signals potential legal or corporate governance concerns that SMTI shareholders may want to monitor closely.
The 3 Wall Street analysts covering Sanara MedTech, Inc. have a median 12-month price target of $35, with estimates ranging from $35 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Sanara MedTech, Inc., 0 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sanara MedTech, Inc. 91 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Aug 2026, Sanara MedTech, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +1.6% from the last close, and Ticker Nerd's factor model ranks Sanara MedTech, Inc. 91 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sanara MedTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $35 over the next 12 months.
Sanara MedTech, Inc. returned +12.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Sanara MedTech Inc. is a medical technology company specializing in developing and commercializing advanced wound care products and technologies.
The most recent item we track (Zacks Investment Research, 12 Aug 2026): "Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates". Sanara MedTech Inc. reported Q2 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.02 per share. This compares favorably to a loss of $0.23 per share in the same quarter last year.
Sanara MedTech Inc. is a medical technology company specializing in developing and commercializing advanced wound care products and technologies. The company's primary focus is on enhancing patient outcomes through innovative solutions that address the complex needs of wound management and skin care. Sanara MedTech offers a comprehensive suite of products, including antimicrobial wound dressings, collagen-based products, and surgical site management solutions, which are designed to improve healing and reduce infection risks in chronic and acute wounds. Operating primarily in the healthcare sector, Sanara MedTech collaborates with healthcare providers, hospitals, and outpatient facilities, providing them with cutting-edge technologies that support efficient patient care. The company's commitment to research and development ensures that it remains at the forefront of innovation in the medical field, addressing some of the significant challenges faced by clinicians today. Sanara MedTech's contributions to the wound care industry underscore its vital role in the market, as it not only aids in advancing medical practices but also promotes improved quality of life for patients worldwide. This has positioned the company as a key player in the healthcare landscape, catering to the increasing demand for effective wound care solutions.
CEO Mr. Seth D. Yon · 108 employees · United States · https://sanaramedtech.com